NVAX Just Completed its Head & Shoulders. Target: $150ishAlright, just look at the chart. Chances are this is a major trend reversal.
NVAX trade ideas
2021 Actual Trade: NVAX +122% ProfitsNVAX provides desirable sideway patterns both from September-November 2020 and December-January 2021 so it gave us a chance to study NVAX from technical and fundamental perspectives.
After we accumulated twice in January 2021, NVAX was discovered and shot to the sky. We took a quick profit first. Then, COVID-19 began to decline, which caused NVAX to slow down also. We decided to close it completely. The highest point we got from NVAX was +122% profits.
It's unbelievable where this is sitting right now..This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100..
Still, many times, you question whether these sharp intraday rallies are the product of market manipulation, as they always seem to happen immediately before heavy sell offs, but who knows..
NVAX coming back 400+ soonHey guys so NVAX had a nice bounce today from its open at 240 and closed at 273.98. It was a solid day I'm not too happy about the volume though due to it being pretty low. The stock is not going to have a tremendous move if there is no volume. We need to have above average volume to see a nice spike above 300 again. Now with the EU news coming possibly end of this week or next week I believe NVAX is going to skyrocket. I am still staying strong with my bullish target of 400 by end of February due to the amount of volume and buy orders we are going to have with the incredible EU deal. Even if EU does not come out this week we still are very oversold on the indicators and have destroyed Pfizer’s new SA variant numbers which show only 20% effectiveness on the new variant. Ours is 60% if you forgot, so we are in good shape right now do not be intimidated by shorts and hold strong!!
NVAX Saw this stock ripping on a Friday afternoon. Took a big position and scaled out the next day to lower cost basis to 106. I traded this stock last year for a great run so I was familiar with what it can do.
NVAX going to 450 late February!! I see a massive spike coming in really soon with NVAX, with the pullback continuing probably till 278 I see an explosion coming!! Around 450 a share is where I see NVAX landing! With RSI, MACD, and William % showing oversold levels I see a reverse coming next week to the uptrend. I hope I am right let us see.
Target price for Novavax..?Novavax is getting ready to test its all time high at 300, but it could go further.
On April 15th 2020, I made the first call on MRNA, NVAX, and INO, to be the companies which will produce COVID-19 vaccine.After 10 months 2 out of 3 have COVID-19 vaccine on the market!
Ever since MRNA has had 468% and NVAX made a decent 1240% gain just in 9 months
This is what I see for NVAX for 2021 huge gains are coming inNVAX stock has had a massive explosion from January where the stock hit 294 a share yesterday. Now I had a prediction that NVAX would break 300 a share by March I think it will be much sooner now. With all the orders and revenue stream that will be produced in 2021, we could see total revenue of 16 billion dollars. I am firmly confident we can reach the same market cap as Moderna as our vaccine is currently more effective and we have more vaccine orders. You may think I am crazy when I predict 1200 a share in a year but if you do the math and see the data it becomes quite convincing. I am not gonna even think about selling until this stock reaches over 500 which I believe could come in May.
Where NVAX is headingBeautiful inverse H&S. Looking for that $350-ish for potential sell or consolidation.
NVAX: Rally nearing conclusion? Possible correction on the way.NASDAQ:NVAX
After an impressive rally, NVAX is lingering in overbought territory which means it's probably time for a correction. Price is approaching Fibonacci levels that typically indicate a reversal or correction. Additionally, there appears to be bearish divergence and my experimental indicator based on TD sequential is signaling that the rally may be is overextended. $300 is psychological resistance - price may test and break that level after market open then quickly retreat to support. NYSE:PFE earning call is today so that could possibly have some ripple into $NVAX price action. There are more point to be made for both the bear and bull case but this is just a quick analysis of how this may play out in the short term
COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 TrialNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants
Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus
Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant
NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK).
Novavax also announced successful results of its Phase 2b study conducted in South Africa.
Significant progress on PREVENT-19 Clinical Trial in US and Mexico
finance.yahoo.com
NVAX 156%After 5 months of consolidation (and 1 month of breakout/consolidation), NVAX looks as if it is ready to pump...we go from a descending wedge breakout to an ascending triangle...bullish divergengence in the macd...as well as a bullish crossover in the macd in positive territory...we should wait for another drop to the 50 day ema ($117)...however, that may not happen...target is $300 (156%)...IT'S YOUR MONEY, DYOR!!
NVAX created a reversal patternAs we can see the price is bouncing up and down creating a sideways direction. This week gives me great hope for a reversal pattern to break above the Darvas Box.
2020 top % NVAX, NIO, TSLA, MCRB, SPWR, ZM, ETH & BTC2020 top % NVAX, NIO, TSLA, MCRB, SPWR, ZM, ETH & BTC
Just to think Bitcoin didn’t gain as much % as I imagined before I did this comparison. It makes me wonder that amazingly Bitcoin has a whole lot more upside potential in 2021?! And I still can't believe I got NVAX for $4.64 in July 2019 only to sell it for $16 in April 2020. lol
Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny a day for a month it = $5,368,709. Good luck and happy trading friends...
*3x lucky 7s of trading*
7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet
7 Common mistakes:
+5% portfolio trades, risk management
Beware of analysts motives
Emotions & Opinions
FOMO : bad timing
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation
7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big organized desk
Reading books, playing chess
Sorted watch-list
Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
TTC - trend channel
www.tradingview.com
Possible downside from hereLooks like there is bad news from novavax, that being that their vaccine isn't effecrive against new strains of virus.
Looks to me that post market has imthe asset pumped up on the cheap in postmarket conditions ripe to be shorted at the open.
Price at end of post market being $170
Vaccine raceThe big stories in the new year, though, could come from vaccines that haven't made it to market yet. It's possible that the stocks of the companies developing these experimental vaccines will deliver tremendous gains over the next 12 months. Here are four coronavirus stocks that are especially poised to soar in 2021.
Of course, they are could be very volatile and uncertain because of the licencing. They are in phase 2 or 3.
Innovio(INO) a small-cap company. It maybe has found its bottom and their vaccine has an advantage in that the drug does not need to be frozen, also announced it entered into a collaborative agreement with Chinese company Advaccine Biopharmaceuticals Suzhou. Their vaccine(INO-4800) could be brought to market within Greater China. Inovio's stock could become a great buy if INO-4800 is successful and the Food and Drug Administration (FDA) approves the vaccine. But the problem is that's not a guarantee.
Altimmun(ALT) a small-cap company. Altimmun could regain the high of summer and something getting started. Their vaccine only requires a single dose. It can be stored at room temperature for extended periods.
Vaxart(VXRT) is a small-cap company. Found its bottom in a sideways consolidation and now something makes investor interested by the last day momentum. Their vaccine could be really cool because It's a single-dose tablet instead of an injection. That makes Vaxart's vaccine more convenient to take and to distribute and store.
Novavax(Nvax) is a mid-cap company. Novavax has a COVID-19/flu combo vaccine. It makes me interested in and I like the sideways consolidation last month or more. Now I waiting for an upward break and it could reach a high of 200 or more.
These forecasts were created to support you, but you have to make your trading decisions independently! Which one could be the winner or loser? Who knows? As nobody sees the future, I recommend you that always apply risk management during your trading and highly recommend the diversification!
$NVAXNovavax, Inc. (NASDAQ:NVAX) closed the Friday session strong right near the high of the day. I think this stock could see $150 next week. Last night after the market's close, the company announced that it has finalized an agreement with the Government of Canada to supply up to 76M doses of NVX-CoV2373, the company's recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52M doses of the vaccine with the option for up to an additional 24M doses. NVX-CoV2373 is currently in Phase 3 clinical development for the prevention of COVID-19. The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency. Looking at the daily technical daily chart the near-term outlook is positive. Momentum indicators are starting to point up, which is a sign of growing strength in the stock and MACD is also giving a positive indication. NVAX will move quickly, so keep it on your screen on Monday.
